Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduc 04/03/13	ed 01/07/96 Origin: Appendix 5 Amended 01/07/98,	, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
Name (of entity	
SHAR	EROOT LIMITED	
ABN		
71 063	3 144 865	
We (t	he entity) give ASX the following	information.
	1 - All issues ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares (Shares)
2	Number of *securities issued or	Up to 954,342,166 Shares
	to be issued (if known) or maximum number which may be issued	Note: Approximate and subject to rounding. Based on the number of Shares which is projected to be on issue as at the record date of 27 June 2019 (Record Date).
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Up to approximately \$954,342.17 at an issue price of 0.1 cents (\$0.001) per Share.

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes.
5	Issue price or consideration	0.1 cents (\$0.001) per Share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	As announced by the Company on 24 June 2019, the Shares will be issued pursuant to a 2-for-3 non-renounceable pro-rata entitlement offer to raise up to approximately \$954,342.17 (before costs) (Entitlement Offer). Proceeds from the Entitlement Offer will be used as follows: • to pay the costs of making the Entitlement Offer; • scale the existing digital services platforms; • complete development of MediaConsent Clinical; and • to fund ongoing working capital and expansion of the business.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 October 2018
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	Up to 954,342,166 Shares (Exception 1). Note: Approximate and subject to rounding. Based on the number of Shares which is projected to be issued as at the Record Date.
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1. Note: This will be updated upon completion of the Entitlement Offer.
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	The issue of Shares under the Entitlement Offer will be issued on or around 19 July 2019.

⁺ See chapter 19 for defined terms.

		Number	+Class
8	Number and +class of all	2,523,796,540	Ordinary Shares
	+securities quoted on ASX (including the +securities in section 2 if applicable)	Note: Approximate and subject to rounding. Based on the number of Shares which is projected to be on issue as at the Record Date.	(SRO)
9	Number and +class of all	Number	+Class
	+securities <u>not quoted</u> on ASX (including the +securities in section 2 if applicable)	4,248,000	Unlisted Options - Expiry earlier of ten years from date of grant or termination of employment Exercisable at \$0.012
		21,000,000	Unlisted Options - Exercisable at A\$0.05 on or before 31 December 2020
		74,783,771	Unlisted Options to employees/advisors under the SRO ESS approved at 2017 AGM
		3,000,000	Unlisted Options – Exercise price of \$0.005 and expiry date of 27 June 2022
		3,666,667	Unlisted Options – Exercise price of \$0.005 and expiry date of 10 November 2022
		11,000,000	Unlisted Options – Exercise price of \$0.005 and expiry date of 8 February 2024
		11,000,000	Unlisted Options – Exercise price of \$0.005 and expiry date of 19 March 2024
		11,000,000	Unlisted Options – Exercise price of \$0.005 and expiry date of 13 May 2024

Part 2	? - Pro rata issue	
11	Is security holder approval required?	No.
12	Is the issue renounceable or non-renounceable?	Non-renounceable.
	5 1.1.1	
13	Ratio in which the +securities will be offered	2 new Shares for every 3 Shares held at the Record Date.
14	+Class of +securities to which the offer relates	Fully paid ordinary shares.
15	+Record date to determine entitlements	27 June 2019.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No.
17	Policy for deciding entitlements in relation to fractions	Rounded down to the nearest number.
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	All countries <u>except</u> for Australia and New Zealand.
19	Closing date for receipt of acceptances or renunciations	5.00 pm (AEST) on 12 July 2019.
20	Names of any underwriters	N/A

N/A

Dividend policy (in the case of a trust, distribution policy) on the

increased capital (interests)

10

⁺ See chapter 19 for defined terms.

21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	The Company reserves the right to pay up to 6% in commission to any broker who assists the Company in placing the shortfall of the Entitlement Offer.
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	No prospectus will be issued, but an offer booklet and a personalised application form will be despatched to eligible shareholders of the Company by no later than 2 July 2019.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	24 June 2019.
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A

33 +Issue date

The issue of Shares under the Entitlement Offer will be issued on or around 19 July 2019.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part 1	
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entitie	s that	have ticked box 34(a)	
Additi	onal s	ecurities forming a new class of securities	
Tick to docume		e you are providing the information or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 100,001 - 100,000 100,001 and over	
37		A copy of any trust deed for the additional *securities	
Entitie	s that	have ticked box 34(b)	
38		ber of *securities for which ation is sought	
39		s of ⁺ securities for which tion is sought	

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation		
	now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all	ranioci	Ciass
42	+securities quoted on ASX (including the +securities in clause 38)		

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.

• An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 24 June 2019

Sign here:

Company Secretary

Print name: David Hwang

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,231,699,788	
Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary securities appealled during that 12 month.	293,754,586	
securities cancelled during that 12 month period		
"A"	1,525,454,374	

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	228,818,156	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	88,000,000	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	88,000,000	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	228,818,156	
Note: number must be same as shown in Step 2		
Subtract "C"	88,000,000	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	140,818,156	

⁺ See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	1,525,454,374	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	[Note: this value cannot be changed]	
Multiply "A" by 0.10	152,545,437	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	152,545,437
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	

<i>Total</i> ["A" x 0.10] – "E"	152,545,437
---------------------------------	-------------

⁺ See chapter 19 for defined terms.